Smoking as one of the predictors of the severity of the condition of patients suffering from a new coronavirus infection

Abstract

The relationship between smoking and the lung damage volume in patients with a confirmed new coronavirus infection diagnosis, hospitalized in a temporary infectious hospital for the treatment of patients suffering from a new coronavirus infection and community-acquired pneumonia was evaluated. This was in the Odintsovo District’s Patriot Park of the Moscow region. Smoking cigarettes, both active and passive, as well as exposure to tobacco smoke on the body, are important upper and lower respiratory tract infection risk factors due to local immune response suppression. Nevertheless, data from a number of international studies indicate a significantly lower number of hospitalized smoking patients compared to non-smokers. These indicators were investigated as the percentage and degree of lung damage, smoking history, the number of cigarettes smoked per day, and the smoker's index. In the course of the study, the data on a smaller percentage of smokers admitted to inpatient treatment were confirmed in comparison with non-smokers and smokers in the general population. There was no statistically significant difference in the volume of lung damage between smoking and non-smoking patients according to the chest organs computed tomography. At the same time, there was an increase in the volume of lung tissue damage, depending on the smoking experience. This is apparently due to the irreversible changes formation in lung tissue against a long-term smoking background. The median age of smoking patients was 56 years with a variation from 46 to 68 years. The minimum and maximum ages were 29 and 82. The median lung lesion was 32% with a variation from 23% to 39%. The minimum and maximum lung damage is 10% and 40%, respectively. A moderate correlation was found between the smoking experience and the volume of lung damage. An increase in lung damage by 0.309% should be expected with an increase in smoking experience by one full year. There was also no statistically significant difference in the number of cigarettes smoked per day and the smoker’s index.

Keywords

new coronavirus infection / pneumoni / smoking / tobacco / angiotensin converting enzyme 2 / nicotine / tobacco smoke / smoking experience / smoker's index

References

[1] Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med. 2020;8(7):475–481. DOI: 10.1016/S2213-2600(20)30239-3

[2] Zyl-Smit R.N., Richards G., Leone F.T. Tobacco smoking and COVID-19 infection // Lancet Respir Med. 2020. Vol. 8, No. 7. P. 475–481. DOI: 10.1016/S2213-2600(20)30239-3

[3] Mustafaev ShM. Analiz riska zdorov'yu pri upotreblenii kal'yanov, ehlektronnykh kuritel'nykh izdelii, sistem dlya nagrevaniya tabaka, kuritel'nykh smesei i tabachnoi/bestabachnoi (nikotinosoderzhashchei) produktsii. Proceeding of the X All-Russian science and practice conference with international participation: «Analiz riska zdorov'yu-2020 sovmestno s mezhdunarodnoi vstrechei po okruzhayushchei srede i zdorov'yu Rise-2020 i kruglym stolom po bezopasnosti pitaniya». 13–15 May 2020. Permian. P. 667–676. (In Russ.).

[4] Мустафаев Ш.М. Анализ риска здоровью при употреблении кальянов, электронных курительных изделий, систем для нагревания табака, курительных смесей и табачной/бестабачной (никотиносодержащей) продукции // Материалы X Всероссийской научно-практической конференции с международным участием: «Анализ риска здоровью-2020 совместно с международной встречей по окружающей среде и здоровью Rise-2020 и круглым столом по безопасности питания»; Май 13–15, 2020; Пермь. C. 667–676.

[5] Evropeiskoe regional'noe byuro VOZ. Doklad o tendentsiyakh v oblasti upotrebleniya tabaka v Evrope 2019 g. Copenhagen: Vsemirnaya organizatsiya zdravookhraneniya, 2019. 68 с. (In Russ.).

[6] Европейское региональное бюро ВОЗ. Доклад о тенденциях в области употребления табака в Европе 2019 г. Копенгаген: Всемирная организация здравоохранения, 2019. 68 с.

[7] Polverino F. Cigarette Smoking and COVID-19: A Complex Interaction. Am J Respir Crit Care Med. 2020;202(3):471–472. DOI: 10.1164/rccm.202005-1646LE

[8] Polverino F. Cigarette Smoking and COVID-19: A Complex Interaction // Am J Respir Crit Care Med. 2020. Vol. 202, No. 3. P. 471–472. DOI: 10.1164/rccm.202005-1646LE

[9] Panasyuk EhI, Agurbash AN. Sravnitel'naya otsenka tyazhesti zabolevaniya COVID-19 u kuryashchikh patsientov. Proceeding of the international science and practice conference: «Meditsina i zdravookhranenie v sovremennom obshchestve». 15 Aug 2020; Penza. Penza: Nauka i prosveshchenie, 2020. P. 9–11. (In Russ.).

[10] Панасюк Э.И., Агурбаш А.Н. Сравнительная оценка тяжести заболевания COVID-19 у курящих пациентов // Сборник статей Международной научно-практической конференции: «Медицина и здравоохранение в современном обществе»; Август 15, 2020; Пенза. Пенза: Наука и просвещение, 2020. С. 9–11.

[11] Ivanov MA, Agurbash AN, Panasyuk EhI. Kurenie kak faktor riska bolee tyazhelogo techeniya COVID-19. Proceeding of the All-Russian science and practice conference with international participation: «Profilakticheskaya meditsina -2020». 18–19 Nov 2020; Saint Petersburg. Saint Petersburg: North-Western State Medical University named after I.I. Mechnikov, 2020. P. 158–163. (In Russ.).

[12] Иванов М.А., Агурбаш А.Н., Панасюк Э.И. Курение как фактор риска более тяжелого течения COVID-19 // Сборник научных трудов Всероссийской научно-практической конференции с международным участием: «Профилактическая медицина-2020»; Ноябрь 18–19, 2020; Санкт-Петербург. Санкт-Петербург: СЗГМУ им. И.И. Мечникова, 2020. С. 158–163.

[13] Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382: 1708–1720. DOI: 10.1056/NEJMoa2002032

[14] Guan W.-J., Ni Z.-Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China // N Engl J Med. 2020. Vol. 382. P. 1708–1720. DOI: 10.1056/NEJMoa2002032

[15] Lawrence H, Hunter A, Murray R, et al. Cigarette smoking and the occurrence of influenza–Systematic review. J Infect. 2019;79(5): 401–406. DOI: 10.1016/j.jinf.2019.08.014

[16] Lawrence H., Hunter A., Murray R., et al. Cigarette smoking and the occurrence of influenza–Systematic review // J Infect. 2019. Vol. 79, No. 5. P. 401–406. DOI: 10.1016/j.jinf.2019.08.014

[17] Leung JM, Sin DD. Smoking, ACE-2 and COVID-19: ongoing controversies. Eur Respir J. 2020;56(1):19–26. DOI: 10.1183/13993003.01759-2020

[18] Leung J.M., Sin D.D. Smoking, ACE-2 and COVID-19: ongoing controversies // Eur Respir J. 2020. Vol. 56, No. 1. P. 19–26. DOI: 10.1183/13993003.01759-2020

[19] Shastri MD, Shukla SD, Chong WC, at al. Smoking and COVID-19: What we know so far. Respir Med. 2021;176:121–128. DOI: 10.1016/j.rmed.2020.106237

[20] Shastri M.D., Shukla S.D., Chong W.C., at al. Smoking and COVID-19: What we know so far // Respir Med. 2021. Vol. 176. P. 121–128. DOI: 10.1016/j.rmed.2020.106237

[21] Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):56–62. DOI: 10.1183/13993003.00688-2020

[22] Leung J.M., Yang C.X., Tam A., et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 // Eur Respir J. 2020. Vol. 55, No. 5. P. 56–62. DOI: 10.1183/13993003.00688-2020

[23] Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020;92(10):1915–1921. DOI: 10.1002/jmv.25889

[24] Zhao Q., Meng M., Kumar R., et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis // J Med Virol. 2020. Vol. 92, No. 10. P. 1915–1921. DOI: 10.1002/jmv.25889

[25] Ivchenko EV, Kotiv BN, Ovchinnikov DV, Bucenko SA. Results of the work of the Military medical academy research institute of novel coronavirus infection problems through 2020–2021. Bulletin of the Russian Military Medical Academy. 2021;23(4):93–104. (In Russ.). DOI: 10.17816/brmma83094

[26] Ивченко Е.В., Котив Б.Н., Овчинников Д.В., Буценко С.А. Результаты работы научно-исследовательского института проблем новой коронавирусной инфекции Военно-медицинской академии за 2020–2021 гг. // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 4. C. 93–104. DOI: 10.17816/brmma83094

[27] Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2): 631–637. DOI: 10.1002/path.1570

[28] Hamming I., Timens W., Bulthuis M.L.C., et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis // J Pathol. 2004. Vol. 203, No. 2. P. 631–637. DOI: 10.1002/path.1570

[29] Yаblonskiy PK, Sukhovskaya OA, Smirnova MA, Vasil’yev VS. Change in smoking behaviour during COVID-19 pandemic. Medical Alliance. 2021;9(3):89–95. (In Russ.). DOI: 10.36422/23076348-2021-9-3-89-95

[30] Яблонский П.К., Суховская О.А., Смирнова М.А., Васильев В.С. Курительное поведение в период пандемии COVID-19 // Медицинский альянс. 2021. Т. 9, № 3. С. 89–95. DOI: 10.36422/23076348-2021-9-3-89-95

[31] Cai G, Bosse Y, Xiao F, et al. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;201(12):1557–1559. DOI: 10.1164/rccm.202003-0693LE

[32] Cai G., Bosse Y., Xiao F., et al. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2 // Am J Respir Crit Care Med. 2020. Vol. 201, No. 12. P. 1557–1559. DOI: 10.1164/rccm.202003-0693LE

[33] Liu W, Tao Z-W, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032–1038. DOI: 10.1097/CM9.0000000000000775

[34] Liu W., Tao Z.-W., Lei W., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease // Chin Med J. 2020. Vol. 133, No. 9. P. 1032–1038. DOI: 10.1097/CM9.0000000000000775

[35] Gambaryan MG, Drapkina OM. Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current publications. Cardiovascular Therapy and Prevention. 2020;19(3):2604. (In Russ.). DOI: 10.15829/1728-8800-2020-2604

[36] Гамбарян М.Г., Драпкина О.М. Курение табака и COVID-19: старый враг в новом обличии. Обзор текущей научной литературы // Кардиоваскулярная терапия и профилактика. 2020. Т. 19, № 3. С. 331–338. DOI: 10.15829/1728-8800-2020-2604

[37] Kashyap VK, Dhasmana A, Massey A, et al. Smoking and COVID-19: Adding Fuel to the Flame. Int J Mol Sci. 2020;21(18):6581. DOI: 10.3390/ijms21186581

[38] Kashyap V.K., Dhasmana A., Massey A., et al. Smoking and COVID-19: Adding Fuel to the Flame // Int J Mol Sci. 2020. Vol. 21, No. 18. ID 6581. DOI: 10.3390/ijms21186581

[39] Williamson EJ, Walker AJ, Bhaskaran KJ, et al. Factors Associated with COVID-19-Related Hospital Death in the Linked Electronic Health Records of 17 Million Adult NHS Patients. OpenSAFELY. 2020;584:430–436. DOI: 10.1038/s41586-020-2521-4

[40] Williamson E.J., Walker A.J., Bhaskaran K.J., et al. Factors Associated with COVID-19-Related Hospital Death in the Linked Electronic Health Records of 17 Million Adult NHS Patients // OpenSAFELY. 2020. Vol. 584. P. 430–436. DOI: 10.1038/s41586-020-2521-4

[41] Mehra MR, Desai SS, Kuy S, et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;382:e102. DOI: 10.1056/NEJMoa2007621

[42] Mehra M.R., Desai S.S., Kuy S., et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 // N Engl J Med. 2020. Vol. 382. ID e102. DOI: 10.1056/NEJMoa2007621

[43] Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med. 2020;15(5):845–852. DOI: 10.1007/s11739-020-02355-7

[44] Farsalinos K., Barbouni A., Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? // Intern Emerg Med. 2020. Vol. 15, No. 5. P. 845–852. DOI: 10.1007/s11739-020-02355-7

[45] Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Medical Council. 2020;(21):96–102. (In Russ.). DOI: 10.21518/2079-701X-2020-21-96-102

[46] Салухов В.В., Харитонов М.А., Крюков Е.В., и др. Актуальные вопросы диагностики, обследования и лечения больных с COVID-19-ассоциированной пневмонией в различных странах и континентах // Медицинский совет. 2020. № 21. С. 96–102. DOI: 10.21518/2079-701X-2020-21-96-102

[47] Cloëz-Tayarani I, Changeux J. Nicotine and serotonin in immune regulation and inflammatory processes: a perspective. J Leukoc Biol. 2007;81(3):599–606. DOI: 10.1189/jlb.0906544

[48] Cloëz-Tayarani I., Changeux J. Nicotine and serotonin in immune regulation and inflammatory processes: a perspective // J Leukoc Biol. 2007. Vol. 81, No. 3. P. 599–606. DOI: 10.1189/jlb.0906544

[49] Cui W-Y, Li MD. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor. J Neuroimmun Pharmacol. 2010;5(4):479–488. DOI: 10.1007/s11481-010-9210-2

[50] Cui W.-Y., Li M.D. Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor // J Neuroimmun Pharmacol. 2010. Vol. 5, No. 4. P. 479–488. DOI: 10.1007/s11481-010-9210-2

[51] Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372–377. DOI: 10.1038/nri803

[52] Sopori M. Effects of cigarette smoke on the immune system // Nat Rev Immunol. 2002. Vol. 2, No. 5. P. 372–377. DOI: 10.1038/nri803

[53] Kolyubaeva SN, Kondratenko AA, Alkhazhe K, et al. Investigation of HLA-DRB1 and IL28 gene polymorphism in patients with varying severity of COVID-19 infection. Genes and cells. 2021;16(3):86–90. (In Russ.). DOI: 10.23868/202110012

[54] Колюбаева С.Н., Кондратенко А.А., Алхаже К., и др. Исследование полиморфизма генов HLA-DRB1 И IL28 у пациентов, перенесших новую коронавирусную инфекцию (COVID-19) c различной степенью тяжести // Гены и Клетки. 2021. Т. 16, № 3. С. 86–90. DOI: 10.23868/202110012

[55] Kryukov EV, Trishkin DV, Salukhov VV, Ivchenko IV. Opyt voennoi meditsiny v bor'be s novoi koronavirusnoi infektsiei. Vestnik Rossijskoj Akademii Nauk. 2022;92(7):699–706. (In Russ.). DOI 10.31857/S086958732207009X

[56] Крюков Е.В., Тришкин Д.В., Салухов В.В., Ивченко И.В. Опыт военной медицины в борьбе с новой коронавирусной инфекцией // Вестник Российской академии наук. 2022. Т. 92, № 7. С. 699–706. DOI 10.31857/S086958732207009X

[57] Wang J, Luo Q, Chen R, et al. Susceptibility Analysis of COVID-19 in Smokers Based on ACE2. Preprints. 2020:2020030078. DOI: 10.20944/preprints202003.0078.v1

[58] Wang J., Luo Q., Chen R., et al. Susceptibility Analysis of COVID-19 in Smokers Based on ACE2 // Preprints. 2020. ID 2020030078. DOI: 10.20944/preprints202003.0078.v1

[59] Minnullin TI, Stepanov AV, Chepur SV, et al. Immunological aspects of SARS-CoV-2 coronavirus damage. Bulletin of the Russian Military Medical Academy. 2021;23(2):187–198. (In Russ.). DOI: 10.17816/brmma72051

[60] Миннуллин Т.И., Степанов А.В., Чепур С.В., и др. Иммунологические аспекты поражения коронавирусом SARS-CoV-2 // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 2. C. 187–198. DOI: 10.17816/brmma72051

[61] Zhang W, Li H, Zhou M, et al. Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front Immunol. 2022;13:826–889. DOI: 10.3389/fimmu.2022.826889

[62] Zhang W., Li H., Zhou M., et al. Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects // Front Immunol. 2022. Vol. 13. Р.826–889. DOI: 10.3389/fimmu.2022.826889

RIGHTS & PERMISSIONS

Eco-Vector